Building A Foundation: Express Scripts’ Miller On Recent Outcomes-Based Contracts
In an interview, the PBM's chief medical officer discusses outcomes-based contracts, comments on whether the drug pricing debate will be impacted by slowing growth in drug spending, and notes an upcoming focus at the PBM on controlling diabetes drug costs
You may also be interested in...
The promise of outcomes-based contracts for biopharmaceuticals has yet to be realized in the US. Although precise numbers are hard to come by, payers and manufacturers agree the field is still nascent. However, they don’t seem to be giving up on the idea.
“Project Indy” offers a joint manufacturer/payor perspective on how to enable value based pricing. It also sounds like a potential proposal to CMS to volunteer for a pilot project.
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.